Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Family Mart Becomes First Convenience Store Chain To Sell OTC Drugs Around The Clock

This article was originally published in PharmAsia News

Executive Summary

Amid more Japanese convenience store chains entering the drug retail business, Family Mart - which employs pharmacists - announced a plan to start selling OTC drugs around the clock in two Tokyo stores beginning in September, becoming the first convenience store chain to do so. The company also plans to expand the program to 300 stores in three years. Compared to current laws allowing only pharmacists to sell both Rx and OTC drugs, a new regulation to take effect April 2009 will enable a registered seller to sell second- and third-class OTC drugs. Since it is easier to recruit registered sellers, stores such as Seven Eleven all have strengthened their drug retail business. (Click here for more - Japanese language) "Family Mart Becomes First Convenience Store Chain Selling OTC Drugs Around The Clock" - FNN News(8/6/08)

You may also be interested in...

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts